Office of the Director, National Institutes of Health; Notice of Meeting, 48320-48321 [2018-20663]

Download as PDF 48320 Federal Register / Vol. 83, No. 185 / Monday, September 24, 2018 / Notices NIAID inventors have identified a multivalent tolerogen (MMPt), which can specifically elicit RICD of the activated, disease causing autoimmune T cells without compromising the general T cell-dependent immunity in the host. Animal studies have demonstrated that MMPt exerts robust therapeutic effects on both monophasic as well as relapsing-remitting type of the disease, indicating its medical applicability for treating MS patients with active disease. NIAID is seeking partners to develop this multi-valent peptide to improve its efficacy for use in clinical trials. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. Potential Commercial Applications: • Therapeutics Competitive Advantages: • Tolerogen induced elimination of activated autoimmune T cells will overcome the fatal side effects of current therapies • Treatment of all types of MS patients Development Stage: amozie on DSK3GDR082PROD with NOTICES1 • Preclinical (In vitro and in vivo animal studies) Inventors: Dr. Michael J. Lenardo (NIAID), Dr. Lixin Zheng (NIAID), Dr. Jian Li (NIAID), Dr. Jae Lee (NIAID), and Dr. Wei Lu (NIAID). Intellectual Property: HHS Reference No. E–064–2015, U.S. Provisional Patent Application Numbers: 62/130,285 filed March 9, 2015 and 62/219,851 filed September 17, 2015, and US PCT application PCT/US2016/021571 filed on March 9, 2016. Entered National Stage filing in US, EU, Canada, and Australia. Licensing Contact: Yogikala Prabhu, Ph.D., 301–761–7789; prabhuyo@ niaid.nih.gov. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the MMPt peptide to improve its efficacy for use in clinical trials. For collaboration opportunities, please contact Yogikala Prabhu, Ph.D., 301–761–7789; prabhuyo@ niaid.nih.gov. VerDate Sep<11>2014 17:40 Sep 21, 2018 Jkt 244001 Dated: September 18, 2018. Suzanne M. Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2018–20664 Filed 9–21–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Office of the Director, National Institutes of Health; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Advisory Committee on Research on Women’s Health. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will also be videocast and can be accessed from the NIH Videocasting and Podcasting website (https:// videocast.nih.gov/). Name of Committee: Advisory Committee on Research on Women’s Health. Date: October 23, 2018. Time: 9:00 a.m. to 4:00 p.m. Agenda: Opening Remarks, Director’s Report, Scientific Presentations, ORWH SCORE Program Update, and Strategic Plan Launch. Place: National Institutes of Health, Building 31, 6th Floor, Conference Room 10, 31 Center Drive, Bethesda, MD 20892. Contact Person: Elizabeth Spencer, R.N., Deputy Director, Office of Research on Women’s Health, Executive Secretary, ACRWH, National Institutes of Health, 6707 Democracy Blvd., Room 7W444, Bethesda, MD 20817, 301–402–1770, elizabeth.spencer@nih.gov. Any member of the public interested in presenting oral comments to the committee may notify the Contact Person listed on this notice at least 10 days in advance of the meeting. Interested individuals and representatives of organizations may submit a letter of intent, a brief description of the organization represented, and a short description of the oral presentation. Only one representative of an organization may be allowed to present oral comments and if accepted by the committee, presentations may be limited to five minutes. Both printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the committee by forwarding their statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: https:// orwh.od.nih.gov/, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS) Dated: September 18, 2018. Ronald J. Livingston, Jr., Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–20665 Filed 9–21–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Office of the Director, National Institutes of Health; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the NIH Clinical Center Research Hospital Board. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. Name of Committee: NIH Clinical Center Research Hospital Board. Date: October 19, 2018. Time: 9:00 a.m. to 3:25 p.m. Agenda: Discussion of Patient Safety. Place: National Institutes of Health, Building 31, 6th Floor, Room: 6C6, 31 Center Drive, Bethesda, MD 20892. Contact Person: Gretchen Wood, Staff Assistant, Office of the Director, National Institutes of Health, One Center Drive, Building 1, Bethesda, MD 20892, 301–496– 4272, woodgs@nih.gov. E:\FR\FM\24SEN1.SGM 24SEN1 Federal Register / Vol. 83, No. 185 / Monday, September 24, 2018 / Notices Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. (Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS) Dated: September 18, 2018. Sylvia L. Neal, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–20663 Filed 9–21–18; 8:45 am] BILLING CODE 4140–01–P ADVISORY COUNCIL ON HISTORIC PRESERVATION Notice of Advisory Council on Historic Preservation Quarterly Business Meeting Advisory Council on Historic Preservation. ACTION: Notice of Advisory Council on Historic Preservation Quarterly Business Meeting. AGENCY: Notice is hereby given that the Advisory Council on Historic Preservation (ACHP) will hold its next quarterly meeting on Thursday, October 4, 2018. The meeting will be held in Room SR325 at the Russell Senate Office Building at Constitution and Delaware Avenues NE, Washington, DC, starting at 8:30 a.m. DATES: The quarterly meeting will take place on Thursday, October 4, 2018 starting at 8:30 a.m. ADDRESSES: The meeting will be held in Room SR325 at the Russell Senate Office Building at Constitution and Delaware Avenues NE, Washington, DC. FOR FURTHER INFORMATION CONTACT: Tanya DeVonish, 202–517–0205, Tdevonish@achp.gov. amozie on DSK3GDR082PROD with NOTICES1 SUMMARY: VerDate Sep<11>2014 17:40 Sep 21, 2018 Jkt 244001 The Advisory Council on Historic Preservation (ACHP) is an independent federal agency that promotes the preservation, enhancement, and sustainable use of our nation’s diverse historic resources, and advises the President and the Congress on national historic preservation policy. The goal of the National Historic Preservation Act (NHPA), which established the ACHP in 1966, is to have federal agencies act as responsible stewards of our nation’s resources when their actions affect historic properties. The ACHP is the only entity with the legal responsibility to encourage federal agencies to factor historic preservation into their decision making. For more information on the ACHP, please visit our website at www.achp.gov. The agenda for the upcoming quarterly meeting of the ACHP is the following: SUPPLEMENTARY INFORMATION: I. Chairman’s Welcome II. Presentation of the ACHP–HUD Award for Historic Preservation Achievement III. Transition to Full-Time ACHP Chair A. Member Questionnaire Responses B. Strategic Plan Development C. Unassembled Meetings IV. Section 106 Issues: A. Department of Veterans Affairs Program Comment on Underutilized Properties B. Proposed Exemption Regarding Railroad and Rail Transit Rights of Way C. Administration Infrastructure Initiatives V. Historic Preservation Policy and Programs: A. White House Initiative on Historically Black Colleges and Universities and the ACHP B. ACHP Approaches to Commenting on Historic Preservation Legislation VI. New Business VII. Adjourn The meetings of the ACHP are open to the public. If you need special accommodations due to a disability, please contact Tanya DeVonish, 202– 517–0205 or tdevonish@achp.gov, at least seven (7) days prior to the meeting. Authority: 54 U.S.C. 304102. Dated: September 17, 2018. Javier E. Marques, General Counsel. [FR Doc. 2018–20675 Filed 9–21–18; 8:45 am] BILLING CODE 4310–K6–P PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 48321 DEPARTMENT OF HOMELAND SECURITY U.S. Customs and Border Protection [1651–0013] Agency Information Collection Activities: Entry and Manifest of Merchandise Free of Duty, Carrier’s Certificate and Release U.S. Customs and Border Protection (CBP), Department of Homeland Security. ACTION: 60-Day notice and request for comments; extension of an existing collection of information. AGENCY: The Department of Homeland Security, U.S. Customs and Border Protection will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (PRA). The information collection is published in the Federal Register to obtain comments from the public and affected agencies. Comments are encouraged and will be accepted (no later than November 23, 2018) to be assured of consideration. ADDRESSES: Written comments and/or suggestions regarding the item(s) contained in this notice must include the OMB Control Number 1651–0013 the subject line and the agency name. To avoid duplicate submissions, please use only one of the following methods to submit comments: (1) Email. Submit comments to: CBP_ PRA@cbp.dhs.gov. (2) Mail. Submit written comments to CBP Paperwork Reduction Act Officer, U.S. Customs and Border Protection, Office of Trade, Regulations and Rulings, Economic Impact Analysis Branch, 90 K Street NE, 10th Floor, Washington, DC 20229–1177. FOR FURTHER INFORMATION CONTACT: Requests for additional PRA information should be directed to Seth Renkema, Chief, Economic Impact Analysis Branch, U.S. Customs and Border Protection, Office of Trade, Regulations and Rulings, 90 K Street NE, 10th Floor, Washington, DC 20229–1177, Telephone number (202) 325–0056 or via email CBP_PRA@cbp.dhs.gov. Please note that the contact information provided here is solely for questions regarding this notice. Individuals seeking information about other CBP programs should contact the CBP National Customer Service Center at 877–227–5511, (TTY) 1–800–877–8339, or CBP website at https://www.cbp. gov/. SUMMARY: E:\FR\FM\24SEN1.SGM 24SEN1

Agencies

[Federal Register Volume 83, Number 185 (Monday, September 24, 2018)]
[Notices]
[Pages 48320-48321]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-20663]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, National Institutes of Health; Notice of 
Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the NIH Clinical Center 
Research Hospital Board.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: NIH Clinical Center Research Hospital Board.
    Date: October 19, 2018.
    Time: 9:00 a.m. to 3:25 p.m.
    Agenda: Discussion of Patient Safety.
    Place: National Institutes of Health, Building 31, 6th Floor, 
Room: 6C6, 31 Center Drive, Bethesda, MD 20892.
    Contact Person: Gretchen Wood, Staff Assistant, Office of the 
Director, National Institutes of Health, One Center Drive, Building 
1, Bethesda, MD 20892, 301-496-4272, [email protected].


[[Page 48321]]


    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    In the interest of security, NIH has instituted stringent 
procedures for entrance onto the NIH campus. All visitor vehicles, 
including taxicabs, hotel, and airport shuttles will be inspected 
before being allowed on campus. Visitors will be asked to show one 
form of identification (for example, a government-issued photo ID, 
driver's license, or passport) and to state the purpose of their 
visit.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, 
Intramural Research Training Award; 93.22, Clinical Research Loan 
Repayment Program for Individuals from Disadvantaged Backgrounds; 
93.232, Loan Repayment Program for Research Generally; 93.39, 
Academic Research Enhancement Award; 93.936, NIH Acquired 
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, 
Undergraduate Scholarship Program for Individuals from Disadvantaged 
Backgrounds, National Institutes of Health, HHS)

    Dated: September 18, 2018.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-20663 Filed 9-21-18; 8:45 am]
 BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.